Navigation Links
Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Date:9/14/2009

rug candidate. The soluble form was developed by Do-Coop which enables SG410 to advance to Tumorgraft testing.
  • The Company conducted its first Personalized Oncology Panel(TM) in Israel and built infrastructure to grow the business there.
  • The Company launched its Personalizedcancertreatment.com website that provides information and access to the Company's personalized treatment program.
  • Furthermore, as previously announced, since the end of the July 31, 2009 quarter, the Company entered into a major collaboration agreement with PinnacleCare, the world's leading private health advisory. This partnership will enable Champions to educate many more physicians regarding the Company's services and assist many more individuals with cutting edge research to personalize their cancer treatment.

    For more information regarding Champions Biotechnology's business and recent news, please visit www.championsbiotechnology.com. To learn more about personalized cancer treatment, please visit www.personalizedcancertreatment.com.

    About Champions Biotechnology, Inc.

    Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest
    '/>"/>

    SOURCE Champions Biotechnology, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
    2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
    3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
    4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
    5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
    6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
    7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
    8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
    9. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
    10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
    11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
    (Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
    (Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
    (Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
    Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
    ... , , , ... now offers new larger pack sizes,of PCR-Grade Nucleotides. These larger pack sizes,combine the best available quality ... , , Single dNTPs , ... Single dNTPs are now available in 500-mol pack sizes.,The Deoxynucleoside Triphosphate Set, containing all four ...
    ... , , ... , , , With the introduction of ... the robust amplification of fragments up to,3 kb, providing the highest possible fidelity ... , , , Pwo Master is a ...
    ... , ... , , , ... for the detection and quantitation,of mRNA species. The assay was made ... T3). These enzymes possess several properties that,make them well suited for ...
    Cached Biology Technology:PCR-Grade Nucleotides,Larger Pack Sizes Now Available 2Pwo Master*:,Simplify Setup of Your Proofreading PCRs 2Pwo Master*:,Simplify Setup of Your Proofreading PCRs 3RNase Protection Assay (RPA),Using DIG-Labeled RNA Probes 2
    (Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
    (Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
    (Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
    Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
    ... led by Simon Fraser University,s Gerontology Research Centre (GRC) ... (SEI) is tracking attitudes about the environment among those ... of organizations, will provide a snapshot of current attitudes ... change. The survey aims to identify difficulties ...
    ... of meanings. Fluid flow in the human body is ... and pathogens that travel through the air. In fact, ... plethora of biological activities. Even the motions of a basketball ... a dynamical system. For the past eight years, ...
    ... have already been introduced into the wild on a ... release of genetically modified animals is still at a ... Max Planck Institute for Evolutionary Biology in Pln, Germany ... of genetically modified insects in Malaysia, USA, and Cayman ...
    Cached Biology News:Survey tracks '55+' attitudes about the environment 2Shane Ross garners CAREER Award to advance understanding of fluid flows from blood inside the body to oil spills in bodies of water 2Shane Ross garners CAREER Award to advance understanding of fluid flows from blood inside the body to oil spills in bodies of water 3Transgene insects: Scientists call for more open data 2Transgene insects: Scientists call for more open data 3Transgene insects: Scientists call for more open data 4
    Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
    Active GST Protein...
    Marmoset plasma and serum - various quantities available...
    Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
    Biology Products: